Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 25, 2008

 

 

PHARMASSET, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-33428   98-0406340

(State or Other Jurisdiction

of Incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

303-A College Road East    
Princeton, NJ     08540
(Address of Principal Executive Offices)     (Zip Code)

Registrant’s telephone number, including area code: (609) 613-4100

 

(Former Name or Former Address, if Changed Since Last Report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 8.01. Other Events.

On April 25, 2008, Pharmasset, Inc. (the “Company”) issued a press release announcing final results of the first and second cohorts of an on-going phase 1 study of R7128, a product candidate the Company is developing with Roche for the treatment of hepatitis C. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

99.1    Press Release, dated April 25, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PHARMASSET, INC.
Date: April 25, 2008   By:  

/s/ KURT LEUTZINGER

  Name:   Kurt Leutzinger
  Title:   Chief Financial Officer

EXHIBIT INDEX

 

Exhibit

Number

  

Description of Exhibit

99.1   Press Release dated April 25, 2008.